{
    "clinical_study": {
        "@rank": "80564", 
        "arm_group": {
            "arm_group_label": "Sunitinib", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether sequential application of low-dose\n      short-term sunitinib and chemotherapy is effective in the treatment of non-small cell lung\n      cancer after failure of conventional therapy. Safety of this regimen will also be evaluated."
        }, 
        "brief_title": "Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Cancer", 
            "Lung Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologic or cytologic diagnosis of stage IIIB/IV NSCLC\n\n          -  ECOG PS: 0,1\n\n          -  Unidimensional or bi-dimensional measurable disease\n\n          -  Receive prior treatment including first-line platinum-based chemotherapy, standard\n             second-line chemotherapy and 1 EGF/EGFR inhibitor\n\n          -  Evidence of disease progression\n\n          -  Life expectancy >12 weeks\n\n          -  Neutrophils > 1.5 109/l, Platelets > 100 109/l, Hemoglobin > 9g/dl, Total bilirubin <\n             1.5 UNL, AST (SGOT) and ALT (SGPT) < 2.5 UNL, Alkaline phosphatases < 5 UNL,\n             Creatinine < 1 UNL\n\n        Exclusion Criteria:\n\n          -  Pre-existing  hemoptysis of a severity > grade 3 by NCI CTCAE criteria within 4 weeks\n             prior to study entry\n\n          -  Uncontrolled hypertension\n\n          -  CHF, angina or arrhythmias\n\n          -  LVEF < 1 UNL\n\n          -  Existing a second malignancy within 5 years\n\n          -  Infected with HIV"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01850147", 
            "org_study_id": "SU-2013-041"
        }, 
        "intervention": {
            "arm_group_label": "Sunitinib", 
            "description": "sunitinib, 12.5mg/day, for 7 days before each cycle of chemotherapy; chemotherapy, single agent including docetaxel, albumin-bound paclitaxel, vinorelbine, gemcitabine, pemetrexed, or paclitaxel, as determined by the investigator", 
            "intervention_name": "Sunitinib, chemotherapy", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Sunitinib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "sunitinib", 
            "chemotherapy", 
            "non-small cell lung cancer", 
            "NSCLC"
        ], 
        "lastchanged_date": "May 7, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100021"
                }, 
                "name": "Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Study of Efficacy and Safety of Sequential Low-dose Sunitinib With Chemotherapy in Advanced Non-small Cell Lung Cancer After Failure of Conventional Regimen", 
        "overall_contact": {
            "email": "drlijunling@yahoo.cn", 
            "last_name": "Junling Li", 
            "phone": "86-13801178891"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective of this study is to evaluate the median progression-free survival of this sequential regimen.", 
            "measure": "progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "up to 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01850147"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese Academy of Medical Sciences", 
            "investigator_full_name": "LI Junling", 
            "investigator_title": "Professor and Chief physician", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate the median over-all survival of this regimen", 
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "up to 2 years"
            }, 
            {
                "description": "To evaluate the disease-control rate of this regimen.", 
                "measure": "disease control rate", 
                "safety_issue": "No", 
                "time_frame": "up to 6 months"
            }, 
            {
                "description": "To evaluate the safety of this regimen including the rate and grade of adverse effects.", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "up to 2 years"
            }
        ], 
        "source": "Chinese Academy of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chinese Academy of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}